Thanh H Dellinger1, David D Smith2, Ching Ouyang3, Charles D Warden4, John C Williams5, Ernest S Han6. 1. Department of Surgery, Division of Gynecologic Oncology, City of Hope National Medical Center, Duarte, CA, United States. Electronic address: tdellinger@coh.org. 2. Biostatistics Unit, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Herston, Australia. 3. Department of Information Sciences, Beckman Research Institute of City of Hope, Duarte, CA, United States; Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States. 4. Integrative Genomics and Bioinformatics Cores, City of Hope Comprehensive Cancer Center, Duarte, CA, United States. 5. Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States. 6. Department of Surgery, Division of Gynecologic Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Abstract
BACKGROUND: L1-cell adhesion molecule (L1CAM) was previously reported to carry a poor prognosis in Stage I, low-risk endometrial cancer (EC). We evaluated the role of L1CAM among all stages and histologies in ECs in The Cancer Genome Atlas (TCGA). METHODS: Clinical information and RNA-Seq expression data were derived from TCGA uterine cancer cohort. Associations between L1CAM expression and clinical factors were tested with linear and logistic regression. Differences in survival between "high" and "low" expression groups (defined by median expression) of L1CAM were compared using Cox regression analysis, with p-values calculated via log-rank test. Kaplan-Meier curves were tested with the log-rank test. RESULTS: Patient characteristics of 545 primary tumors with RNA-Seq gene expression data were analyzed. Median age was 64years (range 31-90). Stage I, II, III, and IV comprised 62%, 10%, 23%, and 5%, respectively. 75% were endometrioid; 21% serous. Grade 1, 2, and 3 comprised 18%, 22%, and 60%, respectively. Median follow-up was 23.0months. High L1CAM expression was associated with advanced stage (OR 3.2), high grade (OR=6.8), serous histology (OR=16.3), positive cytology (OR=3.5), positive pelvic (OR=21.8) and para-aortic lymph nodes (OR=10.3) (all p≤0.001). High L1CAM was associated with a median overall survival (OS) of 107months, versus not reached for low L1-expressing ECs (HR=3.46, CI 1.97-6.07, p<0.001). On multivariate analysis, L1CAM expression remained an independent prognostic variable in predicting OS in EC. CONCLUSIONS: L1CAM expression is an independent predictor of poor survival in endometrial cancer, and is associated with advanced stage, high-risk endometrial cancer.
BACKGROUND:L1-cell adhesion molecule (L1CAM) was previously reported to carry a poor prognosis in Stage I, low-risk endometrial cancer (EC). We evaluated the role of L1CAM among all stages and histologies in ECs in The Cancer Genome Atlas (TCGA). METHODS: Clinical information and RNA-Seq expression data were derived from TCGA uterine cancer cohort. Associations between L1CAM expression and clinical factors were tested with linear and logistic regression. Differences in survival between "high" and "low" expression groups (defined by median expression) of L1CAM were compared using Cox regression analysis, with p-values calculated via log-rank test. Kaplan-Meier curves were tested with the log-rank test. RESULTS:Patient characteristics of 545 primary tumors with RNA-Seq gene expression data were analyzed. Median age was 64years (range 31-90). Stage I, II, III, and IV comprised 62%, 10%, 23%, and 5%, respectively. 75% were endometrioid; 21% serous. Grade 1, 2, and 3 comprised 18%, 22%, and 60%, respectively. Median follow-up was 23.0months. High L1CAM expression was associated with advanced stage (OR 3.2), high grade (OR=6.8), serous histology (OR=16.3), positive cytology (OR=3.5), positive pelvic (OR=21.8) and para-aortic lymph nodes (OR=10.3) (all p≤0.001). High L1CAM was associated with a median overall survival (OS) of 107months, versus not reached for low L1-expressing ECs (HR=3.46, CI 1.97-6.07, p<0.001). On multivariate analysis, L1CAM expression remained an independent prognostic variable in predicting OS in EC. CONCLUSIONS:L1CAM expression is an independent predictor of poor survival in endometrial cancer, and is associated with advanced stage, high-risk endometrial cancer.
Authors: T Bosse; R A Nout; E Stelloo; E Dreef; H W Nijman; I M Jürgenliemk-Schulz; J J Jobsen; C L Creutzberg; V T H B M Smit Journal: Eur J Cancer Date: 2014-08-07 Impact factor: 9.162
Authors: D Gast; S Riedle; Y Issa; M Pfeifer; P Beckhove; M P Sanderson; M Arlt; G Moldenhauer; M Fogel; A Krüger; P Altevogt Journal: Oncogene Date: 2007-10-22 Impact factor: 9.867
Authors: Alexandra Friedli; Eliane Fischer; Ilse Novak-Hofer; Susan Cohrs; Kurt Ballmer-Hofer; P August Schubiger; Roger Schibli; Jürgen Grünberg Journal: Int J Biochem Cell Biol Date: 2009-01-20 Impact factor: 5.085
Authors: Nicole C M Visser; Johan Bulten; Anneke A M van der Wurff; Erik A Boss; Carolien M Bronkhorst; Harrie W H Feijen; Joke E Haartsen; Hilde A D M van Herk; Ineke M de Kievit; Paul J J M Klinkhamer; Brenda M Pijlman; Marc P M L Snijders; Ingrid Vandenput; M Caroline Vos; Peter E J de Wit; Lonneke V van de Poll-Franse; Leon F A G Massuger; Johanna M A Pijnenborg Journal: BMC Cancer Date: 2015-06-30 Impact factor: 4.430
Authors: Uwe Schirmer; Heidi Fiegl; Marco Pfeifer; Alain G Zeimet; Elisabeth Müller-Holzner; Peter K Bode; Verena Tischler; Peter Altevogt Journal: BMC Cancer Date: 2013-03-26 Impact factor: 4.430
Authors: Stefan Kommoss; Andreas D Hartkopf; Bernhard Krämer; Anne-Kathrin Bunz; Friederike Grevenkamp; Felix Kommoss; Jana Pasternak; Sabine M Arbabi; Markus Wallwiener; Annette Staebler; Sigurd F Lax; Sara Y Brucker; Florin-Andrei Taran Journal: J Cancer Res Clin Oncol Date: 2017-07-14 Impact factor: 4.553
Authors: Mac Versluis; A Plat; M de Bruyn; X Matias-Guiu; J Trovic; C Krakstad; H W Nijman; T Bosse; G H de Bock; H Hollema Journal: Virchows Arch Date: 2018-08-23 Impact factor: 4.064
Authors: Jennifer G Haag; Rebecca J Wolsky; Marisa R Moroney; Jamie Sheren; Jeanelle Sheeder; Benjamin G Bitler; Bradley R Corr Journal: Int J Gynecol Pathol Date: 2022-03-14 Impact factor: 3.326
Authors: Cai M Roberts; Michelle A Tran; Mary C Pitruzzello; Wei Wen; Joana Loeza; Thanh H Dellinger; Gil Mor; Carlotta A Glackin Journal: Sci Rep Date: 2016-11-23 Impact factor: 4.379
Authors: Louis Jm van der Putten; Nicole Cm Visser; Koen van de Vijver; Maria Santacana; Peter Bronsert; Johan Bulten; Marc Hirschfeld; Eva Colas; Antonio Gil-Moreno; Angel Garcia; Gemma Mancebo; Fransesc Alameda; Jone Trovik; Reidun K Kopperud; Jutta Huvila; Stefanie Schrauwen; Martin Koskas; Francine Walker; Vit Weinberger; Lubos Minar; Eva Jandakova; Marc Plm Snijders; Saskia van den Berg-van Erp; Xavier Matias-Guiu; Helga B Salvesen; Frederic Amant; Leon Fag Massuger; Johanna Ma Pijnenborg Journal: Br J Cancer Date: 2016-08-09 Impact factor: 7.640